We advised BOM Capital on the sale of its shares in BioNovion to Aduro Biotech. The company, based on the Pivot Park in Oss, is the new European headquarters of Nasdaq-listed Aduro Biotech and renamed in Aduro Biotech Europe. Aduro acquired BioNovion to broaden its technological portfolio and to increase the potential of immunotherapy. BioNovion develops monoclonal antibody therapies against cancer, on the basis of their unique platform technology and expertise in the field of immune therapy of cancer.